Feigenberg Steven J, Lee W Robert, Desilvio Michelle L, Winter Kathryn, Pisansky Thomas M, Bruner Deborah Watkins, Lawton Colleen, Morton Gerald, Baikadi Madhava, Sandler Howard
Department of Radiation Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111-2497, USA.
Int J Radiat Oncol Biol Phys. 2005 Jul 15;62(4):956-64. doi: 10.1016/j.ijrobp.2004.12.061.
To prospectively assess health-related quality of life (HRQOL) during the first year after treatment with prostate brachytherapy (PB) alone for T1c-2a prostate cancer.
Ninety-eight patients from 24 institutions were eligible and properly entered on this study. All patients were treated with PB alone using I-125 (Oncura Model 6711). The prescription dose was 145 Gy. Three separate health-related quality of life questionnaires (HRQOL) (Functional Assessment of Cancer Therapy-Prostate [FACT-P], Sexual Adjustment Questionnaire [SAQ], and International Prostate Symptom Score [IPSS]) were self-administered before and after PB (baseline; 3, 6, 9, and 12 months after PB). The standard error of the mean (SEM) was used to analyze changes in HRQOL scores over time. Patients who improved greater than the SEM were categorized as improved; patients that declined greater than the SEM were categorized as declined; patients were otherwise categorized as stable. All changes are measured using the pretreatment HRQOL score as baseline.
The percentage of men who reported the ability to have an erection decreased from 73% at baseline (65% unassisted, 8% assisted) to 57% at 1 year (36% unassisted, 21% assisted). The rate of urinary incontinence increased to 14% at 6 months but had decreased to 1% at the 12-month follow-up. At 1 year after PB, 80% of men reported decreased sexual functioning according to SAQ scores. More than 60% of men reported decreased urinary function at 12 months compared with baseline.
This article represents the first prospective, multi-institutional study of HRQOL in men treated with PB and demonstrates that patients undergoing PB have a very high overall HRQOL. The rate of incontinence by 1 year after PB is low, but many patients continue to have obstructive symptoms at 1 year. Although 78% of 1-year respondents state that they can achieve an erection with or without assistance, almost 50% report a decrease in sexual function.
前瞻性评估单纯前列腺近距离放疗(PB)治疗T1c - 2a期前列腺癌后第一年的健康相关生活质量(HRQOL)。
来自24家机构的98例患者符合条件并正式纳入本研究。所有患者均单独接受I - 125(Oncura Model 6711)的PB治疗。处方剂量为145 Gy。在PB治疗前后(基线;PB治疗后3、6、9和12个月),患者自行填写三份独立的健康相关生活质量问卷(HRQOL)(癌症治疗功能评估 - 前列腺[FACT - P]、性调整问卷[SAQ]和国际前列腺症状评分[IPSS])。采用均值标准误(SEM)分析HRQOL评分随时间的变化。改善程度大于SEM的患者归类为改善;下降程度大于SEM的患者归类为下降;其他患者归类为稳定。所有变化均以治疗前HRQOL评分为基线进行测量。
报告有勃起能力的男性比例从基线时的73%(65%为自然勃起,8%为辅助勃起)降至1年时的57%(36%为自然勃起,21%为辅助勃起)。尿失禁发生率在6个月时升至14%,但在12个月随访时降至1%。PB治疗1年后,根据SAQ评分,80%的男性报告性功能下降。与基线相比,超过60%的男性在12个月时报告排尿功能下降。
本文是关于接受PB治疗男性HRQOL的首个前瞻性、多机构研究,表明接受PB治疗的患者总体HRQOL非常高。PB治疗1年后尿失禁发生率较低,但许多患者在1年时仍有梗阻性症状。尽管78%的1年随访受访者表示他们无论有无辅助都能勃起,但近5%报告性功能下降。